Keyphrases
Therapeutic Target
100%
Pediatric Malignancy
100%
Pediatric Cancer
60%
PARP Inhibitor (PARPi)
60%
Adult Cancer
40%
Ribosome Biogenesis
40%
Neuroblastoma
20%
Pediatric
20%
Drug Target
20%
Drug Development
20%
Number of Patients
20%
Therapeutic Potential
20%
Publicly Available
20%
Drug Screening
20%
Vulnerability
20%
Cell Viability Assay
20%
Further Development
20%
Medulloblastoma
20%
Therapeutic Approaches
20%
Synergistic Interaction
20%
Topoisomerase Inhibitors
20%
Cause of Disease
20%
Rhabdomyosarcoma
20%
Osteosarcoma
20%
Potential Biomarkers
20%
Ewing Sarcoma
20%
Gene Set Enrichment Analysis
20%
Cancer Cell Lines
20%
Targets of Interest
20%
Disease-related
20%
Chemotherapy Sensitivity
20%
Number of Drugs
20%
High-throughput Drug Screen
20%
Therapeutic Biomarkers
20%
Screening Data
20%
PARP Inhibitor Sensitivity
20%
Cancer Database
20%
Medicine and Dentistry
Pediatrics
100%
Cancer
100%
Poly ADP Ribose Polymerase
100%
Malignant Neoplasm
60%
Pediatric Cancer
60%
Childhood Cancer
40%
Biological Marker
40%
Ribosome
40%
Biogenesis
40%
Ganglioneuroblastoma
20%
Disease
20%
Drug Screening
20%
Drug Sensitivity
20%
Cell Viability Assay
20%
Medulloblastoma
20%
Topoisomerase Inhibitor
20%
Rhabdomyosarcoma
20%
PARP Inhibitor
20%
Ewing Sarcoma
20%
Gene Set Enrichment
20%
Osteosarcoma
20%
Cancer Cell Line
20%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Biological Marker
33%
Childhood Cancer
33%
Neuroblastoma
16%
Drug Screening
16%
Disease
16%
Medulloblastoma
16%
DNA Topoisomerase Inhibitor
16%
Cell Viability
16%
Rhabdomyosarcoma
16%
Osteosarcoma
16%
Viability Assay
16%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
16%
Ewing Sarcoma
16%
Drug Development
16%